WO2006077152A3 - Molecules de fusion hla et utilisations associees - Google Patents

Molecules de fusion hla et utilisations associees Download PDF

Info

Publication number
WO2006077152A3
WO2006077152A3 PCT/EP2006/000560 EP2006000560W WO2006077152A3 WO 2006077152 A3 WO2006077152 A3 WO 2006077152A3 EP 2006000560 W EP2006000560 W EP 2006000560W WO 2006077152 A3 WO2006077152 A3 WO 2006077152A3
Authority
WO
WIPO (PCT)
Prior art keywords
domain
diseases
fusion molecules
hla
fusion molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/000560
Other languages
English (en)
Other versions
WO2006077152A2 (fr
Inventor
Nalan Utku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002595462A priority Critical patent/CA2595462A1/fr
Priority to EP06706364A priority patent/EP1919949A2/fr
Publication of WO2006077152A2 publication Critical patent/WO2006077152A2/fr
Publication of WO2006077152A3 publication Critical patent/WO2006077152A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à une molécule de fusion comportant un premier domaine et un second domaine, ledit premier domaine comportant le domaine HLA-DR alpha 2 ou un fragment de ce domaine. Ladite molécule de fusion a la capacité de moduler la réponse immunitaire médiée par les lymphocytes T. En outre, l'invention se rapporte à des compositions pharmaceutiques comportant ces molécules de fusion et destinées au traitement chez un sujet de diverses maladies du type réaction du greffon contre l'hôte, maladies auto-immunes, maladies allergiques, maladies infectieuses et tumeurs.
PCT/EP2006/000560 2005-01-21 2006-01-23 Molecules de fusion hla et utilisations associees Ceased WO2006077152A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002595462A CA2595462A1 (fr) 2005-01-21 2006-01-23 Molecules de fusion hla et utilisations associees
EP06706364A EP1919949A2 (fr) 2005-01-21 2006-01-23 Molécules de fusion hla et utilisations associées

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64599205P 2005-01-21 2005-01-21
US60/645,992 2005-01-21

Publications (2)

Publication Number Publication Date
WO2006077152A2 WO2006077152A2 (fr) 2006-07-27
WO2006077152A3 true WO2006077152A3 (fr) 2006-10-26

Family

ID=36601159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/000560 Ceased WO2006077152A2 (fr) 2005-01-21 2006-01-23 Molecules de fusion hla et utilisations associees

Country Status (3)

Country Link
EP (1) EP1919949A2 (fr)
CA (1) CA2595462A1 (fr)
WO (1) WO2006077152A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103382224A (zh) * 2013-06-28 2013-11-06 英科隆生物技术（杭州）有限公司 含有四聚体形式的异源交联抗体的异源交联物及其应用
US9943578B2 (en) 2012-05-08 2018-04-17 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of CD4+ T cell populations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009064A1 (fr) * 1997-08-19 1999-02-25 Mount Sinai School Of Medicine Of New York University ; Element de la classe ii du complexe majeur d'histocompatibilite portant un epitope/molecules chimeres d'immunoglobuline
WO1999042597A1 (fr) * 1998-02-19 1999-08-26 President And Fellows Of Harvard College Proteines hybrides monovalentes, multivalentes et multimeres caracterisees par un domaine de liaison cmh (complexe majeur d'histocompatibilite), conjugues de ces proteines, et utilisations correspondantes
WO2001091698A2 (fr) * 2000-06-01 2001-12-06 Gavish Galilee Bio Appl Ltd Molecules du cmh genetiquement modifiees
WO2003025000A2 (fr) * 2001-09-17 2003-03-27 Nalan Utku Peptides capables de moduler une reponse immunitaire

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009064A1 (fr) * 1997-08-19 1999-02-25 Mount Sinai School Of Medicine Of New York University ; Element de la classe ii du complexe majeur d'histocompatibilite portant un epitope/molecules chimeres d'immunoglobuline
WO1999042597A1 (fr) * 1998-02-19 1999-08-26 President And Fellows Of Harvard College Proteines hybrides monovalentes, multivalentes et multimeres caracterisees par un domaine de liaison cmh (complexe majeur d'histocompatibilite), conjugues de ces proteines, et utilisations correspondantes
WO2001091698A2 (fr) * 2000-06-01 2001-12-06 Gavish Galilee Bio Appl Ltd Molecules du cmh genetiquement modifiees
WO2003025000A2 (fr) * 2001-09-17 2003-03-27 Nalan Utku Peptides capables de moduler une reponse immunitaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAG B ET AL: "Functionally active recombinant alpha and beta chain-peptide complexes of human major histocompatibility class II molecules", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 271, no. 17, 26 April 1996 (1996-04-26), pages 10413 - 10418, XP002110049, ISSN: 0021-9258 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9943578B2 (en) 2012-05-08 2018-04-17 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of CD4+ T cell populations
CN103382224A (zh) * 2013-06-28 2013-11-06 英科隆生物技术（杭州）有限公司 含有四聚体形式的异源交联抗体的异源交联物及其应用

Also Published As

Publication number Publication date
WO2006077152A2 (fr) 2006-07-27
EP1919949A2 (fr) 2008-05-14
CA2595462A1 (fr) 2006-07-27

Similar Documents

Publication Publication Date Title
WO2001052791A3 (fr) Complexes de fragments de liaison peptidique de proteines de choc thermique et leur utilisation comme agents immmunotherapeutiques
WO2004010957A3 (fr) Conjugues de medicaments et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
WO2006135434A3 (fr) Oligonucleotides immunostimulateurs de la classe c a squelette partiellement stabilise
WO2007053189A3 (fr) Compositions et méthodes pour altérer une fonction immunitaire
EP2182006A3 (fr) Compositions et procédés pour le traitement de maladies liées au système immunitaire
EP2450360A3 (fr) (S)-N-Méthylnaltrexone
WO2006082406A3 (fr) Proteines et anticorps humains
EP1764370A3 (fr) Méthodes de traitement des maladies inflammatoires en utilisant des liants spécifiques de l'angiopoietin-2 humain
WO2006076594A3 (fr) Anticorps et proteines de fusion fc a immunogenicite modifiee
ATE507204T1 (de) Isoindolin-verbindungen und deren verwendungen
ATE305932T1 (de) Rapanycin29-enole
WO2004029072A3 (fr) Molecules interagissant avec prpsc et utilisations associees
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
CY1112620T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
WO2003027251A3 (fr) Nouvelles molecules de la famille des proteines du domaine de pyrine et leur utilisation
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
WO2004073625A3 (fr) Inhibiteurs de la presentation d'antigenes par des molecules mhc classe i et methodes d'utilisation
WO2005000870A3 (fr) Peptides ny-eso-1 isoles se liant a des molecules hla de classe ii et leurs utilisations
WO2004083241A3 (fr) Proteines interagissant avec btc et utilisation de ces proteines
EP1262491A3 (fr) Vaccines d'IgE non-anaphylactogènes
AU2001292230A1 (en) Parietaria judaica ns-ltp antigen variants, uses thereof and compositions comprising them
WO2007030708A3 (fr) Adzymes antimicrobiens et leurs utilisations
WO2003025000A3 (fr) Peptides capables de moduler une reponse immunitaire
WO2007034490A3 (fr) Peptides diastereomeriques destines a la modulation de l'immunite due aux lymphocytes t

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2595462

Country of ref document: CA

Ref document number: 2007551628

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006706364

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWP Wipo information: published in national office

Ref document number: 2006706364

Country of ref document: EP